Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Global Study to Investigate Combination Regimens Containing Margetuximab for the Treatment of Gastric Cancer

Next Previous
Trial Profile

A Global Study to Investigate Combination Regimens Containing Margetuximab for the Treatment of Gastric Cancer

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 12 Dec 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Margetuximab (Primary)
  • Indications Gastric cancer
  • Focus Therapeutic Use

Most Recent Events

  • 12 Dec 2018 New trial record
  • 29 Nov 2018 According to a MacroGenics media release, MacroGenics and Zai Lab Limited have entered into an exclusive collaboration and license agreement involving three immuno-oncology programs from MacroGenics pipeline of product candidates. As part of this agreement, both the companies intend to initiate this global study using combination regimens containing margetuximab in order to maximize potential clinical benefit in gastric cancer.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top